Nathaniel W. Oswald
Mayo Clinic Hospital(US)
Publications by Year
Research Areas
RNA modifications and cancer, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses, RNA Interference and Gene Delivery, Testicular diseases and treatments
Most-Cited Works
- → Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan(2017)153 cited
- → Ikarugamycin: A Natural Product Inhibitor of Clathrin‐Mediated Endocytosis(2016)84 cited
- → Precursor-directed generation of amidine containing ammosamide analogs: ammosamides E–P(2012)77 cited
- → HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress(2018)66 cited
- → FUSION-Guided Hypothesis Development Leads to the Identification of N6,N6-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor(2017)16 cited
- → Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer(2023)8 cited
- → Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study(2023)7 cited
- → Factors associated with appropriate and low-value PSA testing(2020)4 cited
- → Author Correction: Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan(2018)4 cited
- → Supplementary Figures from HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress(2023)